Patent US4554159A successfully refreshed from Google Patents.
US4554159A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Vaccine and method of immunizing against herpes simplex virus (types 1 and 2)
Assignee: Institut Merieux SA
•
Filing: 1981-11-12
•
Granted: 1985-11-19
•
Expires: 2001-11-12
Abstract
Abstract A live viral vaccine against herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) incorporates as an effective ingredient at least one intertypic (HSV-1xHSV-2) vaccinal recombinant virus strain.
Inventors
- 👤 Bernard Roizman
- 👤 M. Robert Lang
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 10:22
CPC Classifications
A; A61; A61K; A61K39/00; A61K39/12; A61K39/245; C; C12; C12N; C12N2710/00; C12N2710/00011; C12N2710/16011; C12N2710/16611; C12N2710/16634
Claims Analysis
Total Claims: 38
Claim 1
Independent Claim
143 words
A live viral vaccine which is effective against wild-type HSV-1 and HSV-2, said vaccine comprising an immunity-including dose of at least one vaccinal intertypic (HSV-1×HSV-2) recombinant virus strain, said strain being prepared by the method comprising the steps of: (a) crossing two prototypical HSV-1 and HSV-2 parental virus strains to obtain recombinant progeny, said parental strains having distinguishing genetic markers such that said recombinant progeny can be distinguished from said parental strains on the basis of said markers, at least one of said parental strains being distinguished by a temperature sensitive phenotype; (b) identifying recombinant progeny distinguished by a temperature resistant phenotype; (c) isolating said recombinant progeny of (b) from said parental strains and from recombinant progeny having a temperature sensitive phenotype; and, (d) selecting from said temperature resistant progeny those strains which exhibit vaccinal characteristics with respect to wild-type HSV-1 and HSV-2.
Claim 2
Dependent Claim
143 words
A live viral vaccine which is effective against wild-type HSV-1 and HSV-2, said vaccine comprising an immunity-including dose of at least one vaccinal intertypic (HSV-1×HSV-2) recombinant virus strain, said strain being prepared by the method comprising the steps of: (a) crossing two prototypical HSV-1 and HSV-2 parental virus strains to obtain recombinant progeny, said parental strains having distinguishing genetic markers such that said recombinant progeny can be distinguished from said parental strains on the basis of said markers, at least one of said parental strains being distinguished by a temperature sensitive phenotype; (b) identifying recombinant progeny distinguished by a temperature resistant phenotype; (c) isolating said recombinant progeny of (b) from said parental strains and from recombinant progeny having a temperature sensitive phenotype; and, (d) selecting from said temperature resistant progeny those strains which exhibit vaccinal characteristics with respect to wild-type HSV-1 and HSV-2.
Claim 3
Dependent Claim
30 words
The vaccine of claim 1 wherein said selection is effected by empirical determination of avirulence, stability with respect to avirulence, immunogenicity, and latency, with respect to wild-type HSV-1 and HSV-2.
Claim 4
Independent Claim
149 words
A method of immunizing a human host against wild-type HSV-1 and HSV-2, said method comprising the step of inoculating said host with an immunity including dose of a live viral vaccine which comprises at least one vaccinal intertypic (HSV-1×HSV-2) recombinant virus strain prepared by the steps of: (a) crossing two prototypical HSV-1 and HSV-2 parental virus strains to obtain recombinant progeny, said parental strains having distinguishing genetic markers such that said recombinant progeny can be distinguished from said parental strains on the basis of said markers, at least one of said parental strains being distinguished by a temperature sensitive phenotype; (b) identifying recombinant progeny distinguished by a temperature resistant phenotype; (c) isolating said recombinant progeny of (b) from said parental strains and from recombinant progeny having a temperature sensitive phenotype; and, (d) selecting from said progeny those strains which exhibit vaccinal characteristics with respect to wild-type HSV-1 and HSV-2.
Claim 5
Independent Claim
149 words
A method of immunizing a human host against wild-type HSV-1 and HSV-2, said method comprising the step of inoculating said host with an immunity including dose of a live viral vaccine which comprises at least one vaccinal intertypic (HSV-1×HSV-2) recombinant virus strain prepared by the steps of: (a) crossing two prototypical HSV-1 and HSV-2 parental virus strains to obtain recombinant progeny, said parental strains having distinguishing genetic markers such that said recombinant progeny can be distinguished from said parental strains on the basis of said markers, at least one of said parental strains being distinguished by a temperature sensitive phenotype; (b) identifying recombinant progeny distinguished by a temperature resistant phenotype; (c) isolating said recombinant progeny of (b) from said parental strains and from recombinant progeny having a temperature sensitive phenotype; and, (d) selecting from said progeny those strains which exhibit vaccinal characteristics with respect to wild-type HSV-1 and HSV-2.
Claim 6
Dependent Claim
30 words
The method of claim 3 wherein said selection is effected by empirical determination of avirulence, stability with respect to avirulence, immunogenicity, and latency, with respect to wild-type HSV-1 and HSV-2.
Claim 7
Dependent Claim
36 words
The method of claim 3 or 4 wherein said host lacks immunity to said wild-type HSV-1 and HSV-2 and faces a high probability of natural infection by either or both of said wild-type HSV-1 and HSV-2.
Claim 8
Dependent Claim
25 words
The method of claim 3 or 4 wherein said host lacks immunity to said wild-type HSV-1 and HSV-2 and is likely to become immunologically compromised.
Claim 9
Dependent Claim
31 words
The method of claim 3 or 4 wherein said host lacks immunity to said wild-type HSV-1 and HSV-2 and is likely to become immunologically compromised as a result of immunosuppressive therapy.
Claim 10
Independent Claim
92 words
A method of immunizing a human host against virulent HSV-1 and HSV-2, which method comprises the step of inoculating said host with a live viral vaccine which comprises as an effective ingredient at least one stable, avirulent intertypic (HSV-1×HSV-2) recombinant virus strain selected from the group consisting of the strains designated A5C (ATCC No. VR 2019), D4E1 (ATCC No. VR 2020), D4E3 (ATCC No. VR 2021), C7D (ATCC No. VR 2022), D4E2 (ATCC No. VR 2023), C5D (ATCC No. VR 2024), D5E1 (ATCC No. VR 2025) and D1E1 (ATCC No. VR 2026).
Claim 11
Independent Claim
92 words
A method of immunizing a human host against virulent HSV-1 and HSV-2, which method comprises the step of inoculating said host with a live viral vaccine which comprises as an effective ingredient at least one stable, avirulent intertypic (HSV-1×HSV-2) recombinant virus strain selected from the group consisting of the strains designated A5C (ATCC No. VR 2019), D4E1 (ATCC No. VR 2020), D4E3 (ATCC No. VR 2021), C7D (ATCC No. VR 2022), D4E2 (ATCC No. VR 2023), C5D (ATCC No. VR 2024), D5E1 (ATCC No. VR 2025) and D1E1 (ATCC No. VR 2026).
Claim 12
Dependent Claim
18 words
The method of claim 8 wherein said recombinant strain comprises the strain designated A5C (ATCC No. VR 2019).
Claim 13
Dependent Claim
18 words
The method of claim 8 wherein said recombinant strain comprises the strain designated D4E1 (ATCC No. VR 2020).
Claim 14
Dependent Claim
18 words
The method of claim 8 wherein said recombinant strain comprises the strain designated D4E3 (ATCC No. VR 2021).
Claim 15
Dependent Claim
18 words
The method of claim 8 wherein said recombinant strain comprises the strain designated C7D (ATCC No. VR 2022).
Claim 16
Dependent Claim
18 words
The method of claim 8 wherein said recombinant strain comprises the strain designated D3E2 (ATCC No. VR 2023).
Claim 17
Dependent Claim
18 words
The method of claim 8 wherein said recombinant strain comprises the strain designated C5D (ATCC No. VR 2024).
Claim 18
Dependent Claim
18 words
The method of claim 8 wherein said recombinant strain comprises the strain designated D5E1 (ATCC No. VR 2025).
Claim 19
Dependent Claim
18 words
The method of claim 8 wherein said recombinant strain comprises the strain designated D1E1 (ATCC No. VR 2026).
Claim 20
Independent Claim
95 words
A method of immunizing a human host against virulent HSV-1 and HSV-2, which method comprises the step of inoculating said host with a live viral vaccine which comprises as an effective ingredient at least one stable, avirulent, intertypic (HSV-1×HSV-2) recombinant strain having the identifying characteristics of a strain selected from the group consisting of A5C (ATCC No. VR 2019), D4E1 (ATCC No. VR 2020), D4E3 (ATCC No. VR 2021), C7D (ATCC No. VR 2022), D3E2 (ATCC No. VR 2023), C5D (ATCC No. VR 2024), D5E1 (ATCC No. VR 2025) and D1E1 (ATCC No. VR 2026).
Claim 21
Independent Claim
95 words
A method of immunizing a human host against virulent HSV-1 and HSV-2, which method comprises the step of inoculating said host with a live viral vaccine which comprises as an effective ingredient at least one stable, avirulent, intertypic (HSV-1×HSV-2) recombinant strain having the identifying characteristics of a strain selected from the group consisting of A5C (ATCC No. VR 2019), D4E1 (ATCC No. VR 2020), D4E3 (ATCC No. VR 2021), C7D (ATCC No. VR 2022), D3E2 (ATCC No. VR 2023), C5D (ATCC No. VR 2024), D5E1 (ATCC No. VR 2025) and D1E1 (ATCC No. VR 2026).
Claim 22
Independent Claim
53 words
A method of immunizing a human host against virulent HSV-1 and HSV-2, which method comprises the step of inoculating said host with a live viral vaccine which comprises as an effective ingredient at least one stable, avirulent, intertypic (HSV-1×HSV-2) recombinant strain having the BamH1 and Kpn1 fingerprints shown in FIGS. 1 and 2.
Claim 23
Independent Claim
53 words
A method of immunizing a human host against virulent HSV-1 and HSV-2, which method comprises the step of inoculating said host with a live viral vaccine which comprises as an effective ingredient at least one stable, avirulent, intertypic (HSV-1×HSV-2) recombinant strain having the BamH1 and Kpn1 fingerprints shown in FIGS. 1 and 2.
Claim 24
Dependent Claim
79 words
A live viral vaccine against virulent HSV-1 and HSV-2 which comprises as an effective ingredient an immunity-inducing dose of at least one stable, avirulent intertypic (HSV-1×HSV-2) recombinant virus strain selected from the group consisting of the strains designated A5C (ATCC No. VR 2019), D4E1 (ATCC No. VR 2020), D4E3 (ATCC No. VR 2021), C7D (ATCC No. VR 2022), D5E2 (ATCC No. VR 2023), C5D (ATCC No. VR 2024), D5E1 (ATCC No. VR 2025) and D1E1 (ATCC No. VR 2026).
Claim 25
Dependent Claim
79 words
A live viral vaccine against virulent HSV-1 and HSV-2 which comprises as an effective ingredient an immunity-inducing dose of at least one stable, avirulent intertypic (HSV-1×HSV-2) recombinant virus strain selected from the group consisting of the strains designated A5C (ATCC No. VR 2019), D4E1 (ATCC No. VR 2020), D4E3 (ATCC No. VR 2021), C7D (ATCC No. VR 2022), D5E2 (ATCC No. VR 2023), C5D (ATCC No. VR 2024), D5E1 (ATCC No. VR 2025) and D1E1 (ATCC No. VR 2026).
Claim 26
Dependent Claim
18 words
The vaccine of claim 19 wherein said recombinant strain comprises the strain designated A5C (ATCC No. VR 2019).
Claim 27
Dependent Claim
18 words
The vaccine of claim 19 wherein said recombinant strain comprises the strain designated D4E1 (ATCC No. VR 2020).
Claim 28
Dependent Claim
18 words
The vaccine of claim 19 wherein said recombinant strain comprises the strain designated D4E3 (ATCC No. VR 2021).
Claim 29
Dependent Claim
18 words
The vaccine of claim 19 wherein said recombinant strain comprises the strain designated C7D (ATCC No. VR 2022).
Claim 30
Dependent Claim
18 words
The vaccine of claim 19 wherein said recombinant strain comprises the strain designated D3E2 (ATCC No. VR 2023).
Claim 31
Dependent Claim
18 words
The vaccine of claim 19 wherein said recombinant strain comprises the strain designated C5D (ATCC No. VR 2024).
Claim 32
Dependent Claim
18 words
The vaccine of claim 19 wherein said recombinant strain comprises the strain designated D5E1 (ATCC No. VR 2025).
Claim 33
Dependent Claim
18 words
The vaccine of claim 19 wherein said recombinant strain comprises the strain designated D1E1 (ATCC No. VR 2026).
Claim 34
Dependent Claim
38 words
A method of treating a human subject infected with wild-type HSV-1 or HSV-2, or both, said method comprising the step of administering to said subject an effective dose of the vaccine of claim 1, 2, 19 or 30.
Claim 35
Dependent Claim
36 words
A live viral vaccine against virulent HSV-1 and HSV-2 which comprises as an effective ingredient at least one stable, avirulent, intertypic (HSV-1×HSV-2) recombinant strain having the BamH1 and Kpn1 fingerprints shown in FIGS. 1 and 2.
Claim 36
Dependent Claim
36 words
A live viral vaccine against virulent HSV-1 and HSV-2 which comprises as an effective ingredient at least one stable, avirulent, intertypic (HSV-1×HSV-2) recombinant strain having the BamH1 and Kpn1 fingerprints shown in FIGS. 1 and 2.
Claim 37
Dependent Claim
17 words
The vaccine of claim 1 comprising between about 10 and 10,000 plaque-forming units of said vaccinal strain.
Claim 38
Dependent Claim
20 words
The method of claim 3 wherein said vaccine comprises between about 10 and 10,000 plaque-forming units of said vaccinal strain.
References Cited (Backward Citations)
US4206287A
Cited
US4009258A
Cited
US3992522A
Cited
US3897549A
Cited
US3991179A
Cited
US4029763A
Cited
US4147772A
Cited
US4318903A
Cited
US4337314A
Cited
US4381903A
Cited
US4278662A
Cited
US4322404A
Cited
US4317811A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1988-11-18 | 1989-05-20 | 1989-11-19 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1992-11-18 | 1993-05-20 | 1993-11-19 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1996-11-18 | 1997-05-20 | 1997-11-19 | $7700.00 | Window Closed / Lapsed |